Loading filters...
50 results(scroll for more)
MSI-H/dMMRAdvanced/Metastatic (IV)2026
Revised Tumor Burden Score for Prognostic Stratification in Metastatic Colorectal Cancer Patients Receiving Immunotherapy: A Retrospective Study.
Zhang YY et al. Oncologist. 2026
GeneralEarly (I-III)2026
Impact of Obesity on Postoperative Outcomes in Transanal Total Mesorectal Excision for Rectal Cancer.
Zewde MG et al. Dis Colon Rectum. 2026
GeneralAdvanced/Metastatic (IV)2026
Drink Responsibly: Cancer Cells Also Like Sugary Drinks.
Zani F et al. Cancer Res. 2026
MSI-H/dMMRAdvanced/Metastatic (IV)2026
Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer.
Yeh C et al. Clin Cancer Res. 2026
MSI-H/dMMREarly (I-III)2026
Consensus guidance of immune checkpoint inhibitors in locally advanced rectal cancer.
Yang Z et al. Gut. 2026
GeneralAdvanced/Metastatic (IV)2026
Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study.
Liu X et al. ESMO Open. 2026
MSI-H/dMMRAll Stages2026
Dual mechanism of immune escape shapes the genetic and immunogenic landscape of mismatch repair-deficient colorectal tumours.
Xavier-Ferreira H et al. Gut. 2026
GeneralAll Stages2026
Oxaliplatin-induced neuropathy after total neoadjuvant therapy for rectal cancer: Dose-response relationship and impact on quality of life.
Wurschi GW et al. Int J Cancer. 2026
GeneralAll Stages2026
The perioperative microbiome of patients undergoing rectal cancer surgery: A pilot study.
Wienholts K et al. Colorectal Dis. 2026
GeneralEarly (I-III)2026
Treatment Adequacy and Baseline Risk Modify the Association Between Adjuvant Chemotherapy and Survival After Pathological Complete Response in Rectal Cancer.
Wang C et al. Int J Cancer. 2026
GeneralAll Stages2026
Exosomal miRNA Predicts Response to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer.
Wada Y et al. Dis Colon Rectum. 2026
GeneralEarly (I-III)2026
Cost-Effectiveness of Pelvic Floor Reconstruction Using Biological Mesh After Extralevator Abdominoperineal resection for Rectal Cancer.
van den Berg R et al. Dis Colon Rectum. 2026
GeneralAdvanced/Metastatic (IV)2026
Third-line treatment decision-making for metastatic colorectal cancer: a cross-sectional survey of US community physicians.
Cann C et al. Oncologist. 2026
GeneralAll Stages2026
A standardised approach to the pathological dissection and reporting of pelvic exenteration specimens: Recommendations from the UK Pelvic Exenteration Network (UKPEN).
Aldridge J et al. Colorectal Dis. 2026
GeneralAll Stages2026
Laparoscopic Sacrectomy as Part of En Bloc Resection for Locally Recurrent Rectal Cancer.
Uemura M et al. Dis Colon Rectum. 2026
GeneralAll Stages2026
TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis.
Mödl B et al. Cancer Res. 2026
RAS wild-typeAll Stages2026
TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab.
Fountzilas C et al. Int J Cancer. 2026
GeneralAll Stages2026
Development and validation of web-based prediction models for major low anterior resection syndrome at 3 and 6 months after sphincter-preserving surgery in patients with rectal cancer.
Sun L et al. Int J Colorectal Dis. 2026
GeneralEarly (I-III)2026
Gut microbiota-associated predictors as biomarkers of neoadjuvant treatment response in rectal cancer-a systematic review.
Stepanyan A et al. Br J Cancer. 2026
GeneralAdvanced/Metastatic (IV)2026
SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts.
Liu S et al. Cancer Res. 2026
Biomarker/ctDNAAll Stages2026
ColoStem, a core oncofetal signature that identifies poor prognosis colorectal tumors.
Solé L et al. Br J Cancer. 2026
GeneralEarly (I-III)2026
Added value of adjuvant chemotherapy in patients with node-positive pT1-2 Colon cancer - A national SNAPSHOT analysis.
Hanevelt J et al. Oncologist. 2026
Biomarker/ctDNAEarly (I-III)2026
Cancer-associated fibroblast signature and SMAD4 mutation in resistance to adjuvant chemotherapy in stage III colon cancer patients.
Franken IA et al. Eur J Cancer. 2026
MSI-H/dMMRAdvanced/Metastatic (IV)2026
Predictors of Immune Checkpoint Blockade Response in dMMR Colorectal Cancer Using an Integrated Immune-Enhanced Multi-Omics Platform.
Sinicrope FA et al. Clin Cancer Res. 2026
GeneralEarly (I-III)2026
Effect of prolonged interval between neoadjuvant chemoradiotherapy and surgery on pathological and oncological outcomes in locally advanced rectal cancer: a randomized controlled trial.
Sileika E et al. Int J Colorectal Dis. 2026
GeneralEarly (I-III)2026
Dynamic ctDNA Monitoring Guides Early Treatment Intensification in Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemotherapy.
Shen Y et al. Clin Cancer Res. 2026
GeneralEarly (I-III)2026
Early evaluation of the low anterior resection syndrome after sphincter sparing rectal cancer surgery and prompt treatment: a cohort study protocol.
Sguinzi R et al. Int J Colorectal Dis. 2026
GeneralEarly (I-III)2026
Long-term outcomes of pT1 rectal cancer after transanal endoscopic surgery: again, a word of caution on high local recurrence - a cohort study.
Serra-Aracil X et al. Int J Colorectal Dis. 2026
GeneralEarly (I-III)2026
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial.
Iveson T et al. J Clin Oncol. 2026
Biomarker/ctDNAAll Stages2026
New prognostic and predictive scoring systems for colorectal cancer liver metastases.
Salvà F et al. ESMO Open. 2026
GeneralAdvanced/Metastatic (IV)2026
Young adults undergoing anterior resection for colorectal cancer experience fewer medical complications but a comparable risk of anastomotic leak.
Rudasill SE et al. Colorectal Dis. 2026
GeneralEarly (I-III)2026
Living 20 years with perineal colostomy and dynamic graciloplasty - a case report discussing the role of this approach.
Rosen H et al. Int J Colorectal Dis. 2026
Biomarker/ctDNAAdvanced/Metastatic (IV)2026
Impact of treatment discontinuation among patients with microsatellite instability or mismatch repair-deficient metastatic colorectal cancer treated with immune checkpoint inhibitors.
Ros J et al. ESMO Open. 2026
GeneralEarly (I-III)2026
Rectal Cancer in the Elderly: To Operate or Not to Operate? A Nationwide Retrospective Study of the Italian Society of Surgical Oncology-Colorectal Cancer Network Collaborative Group.
Reddavid R et al. Dis Colon Rectum. 2026
RAS wild-typeAdvanced/Metastatic (IV)2026
ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial.
Manca P et al. Clin Cancer Res. 2026
RAS wild-typeAdvanced/Metastatic (IV)2026
Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE.
Potthoff K et al. Int J Cancer. 2026
BRAF V600EAdvanced/Metastatic (IV)2026
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO.
Ciracì P et al. Ann Oncol. 2026
MSI-H/dMMRAdvanced/Metastatic (IV)2026
Impact of RAS/BRAFV600E Mutations on the Tumor Immune Microenvironment in Mismatch Repair-Deficient/Microsatellite Instability Colorectal Cancers.
Salem ME et al. Clin Cancer Res. 2026
GeneralAdvanced/Metastatic (IV)2026
Genetic differences between primary colorectal cancer and its paired synchronous and metachronous metastases.
Rajtmajerova M et al. Int J Cancer. 2026
GeneralEarly (I-III)2026
Deep impact analysis of surgical strategy changes guided by indocyanine green fluorescence angiography in laparoscopic low anterior resection for rectal cancer.
Qiu X et al. Int J Colorectal Dis. 2026
Biomarker/ctDNAAdvanced/Metastatic (IV)2026
Noninvasive diagnosis of colorectal adenoma: The emerging potential of blood-based biomarkers.
Qi CY et al. World J Gastroenterol. 2026
MSI-H/dMMREarly (I-III)2026
Bifidobacterium catenulatum boosts anti-PD-1 efficacy in microsatellite stable colorectal cancer via activating CD8+ T cells.
Li X et al. Gut. 2026
GeneralEarly (I-III)2026
Disruptive Analysis of Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Clinical and Therapeutic Distinctions Between Low- and Mid-Rectal Cancers.
Noiret B et al. J Clin Oncol. 2026
GeneralAdvanced/Metastatic (IV)2026
eIF3i facilitates NELFCD translation to promote metastasis via regulating EMT and invadopodia.
Huang Q et al. Br J Cancer. 2026
MSI-H/dMMRAdvanced/Metastatic (IV)2026
Mucinous histology and resistance to immune checkpoint blockade in patients with microsatellite instability-high metastatic colorectal cancer.
Nasca V et al. Oncologist. 2026
MSI-H/dMMRAll Stages2026
Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy.
Iglesias Coma M et al. Gut. 2026
GeneralAll Stages2026
Clinical utility of longitudinal ctDNA monitoring by multiplex MS-ddPCR for risk stratification and follow-up in rectal cancer.
Lauridsen ED et al. Int J Colorectal Dis. 2026
MSI-H/dMMRAll Stages2026
Evaluating MRI response criteria in microsatellite instability-high rectal cancer treated with immune checkpoint inhibitors.
Vanderbecq Q et al. ESMO Open. 2026
GeneralAll Stages2026
An interpretable machine learning model based on MRI radiomics and GAME score for predicting early recurrence after thermal ablation in colorectal liver metastases.
Kong Y et al. Int J Colorectal Dis. 2026
GeneralEarly (I-III)2026
The significance of MRI-detected lateral lymph node metastasis in rectal cancer on local recurrence and survival-A nationwide cohort study.
Agger E et al. Colorectal Dis. 2026